Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 1, 2011, Pages

  Chakrabarti, Swarup K ^a   Wen, Yeshao ^b   Dobrian, Anca D ^a   Cole, Banumathi K ^a   Ma, Qian ^a   Pei, Hong ^b   Williams, Michael D ^b   Bevard, Melissa H ^b   Vandenhoff, George E ^b   Keller, Susanna R ^b   Gu, Jiali ^b   Nadler, Jerry L ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

12 Hydroxyeicosatetraenoic acid; 3T3 L1 adipocytes; 5 hydroxyeicosatetraenoic acid; Interleukin 6; Monocyte chemoattractant protein 1

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CYTOKINE; INTERLEUKIN 6; LEUKOTRIENE B4; LISOFYLLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT4 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; INFLAMMATION; INTRAABDOMINAL FAT; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; ZUCKER RAT;

3T3-L1 CELLS; 5-LIPOXYGENASE-ACTIVATING PROTEINS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACIDS; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; INTRA-ABDOMINAL FAT; MICE; OBESITY; PENTOXIFYLLINE; PHOSPHORYLATION; RATS; RATS, ZUCKER; RNA, MESSENGER; STAT4 TRANSCRIPTION FACTOR;

EID: 78650788269     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00203.2010     Document Type: Article

References (70)

1. Adorini L. Interleukin 12 and autoimmune diabetes. Nat Genet 27: 131-132, 2001.
2. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky JM, Karin M. IKK-β links inflammation to obesity induced insulin resistance. Nat Med 11: 191-198, 2005.
3. Bäck M, Sultan A, Ovchinnikova O, Hansson GK. 5-Lipoxygenase- activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 100: 946-949, 2007.
4. Balon TW, Jasman AP, Bwisten SL, Nadler JL. Lisofylline, a modulator of fatty acid metabolism, increases peripheral insulin sensitivity (Abstract). Diabetes 48, Suppl 1: 411, 2000.
5. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87: 2084-2089, 2002.
6. Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S, Bickel PE, Pessin JE, Saltiel AR. CAP defines a second signaling pathway required for insulin-stimulated glucose transport. Nature 407: 202-207, 2000.
7. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96: 939-949, 2005. (Pubitemid 40712793)
8. Bleich D, Chen S, Gu JL, Thomas L, Scott S, Gonzales N, Natarajan R, Nadler JL. Interleukin-1 beta regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells. Endocrinology 136: 5736-5744, 1995.
9. Bray GA. The Zucker-fatty rat: a review. Fed Proc 36: 148-153, 1977.
10. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 11: 525-531, 2003.
11. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL. 12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity (Silver Spring) 17: 1657-1663, 2009.
12. Chakrabarti SK, James JC, Mirmira RG. Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. J Biol Chem 277: 13286-13293, 2002.
13. Chen M, Yang MD, Smith KM, Carter JD, Nadler JL. Activation of 12-lipoxygenase in pro-inflammatory cytokine-mediated beta cell toxicity. Diabetologia 48: 486-495, 2005.
14. Coon ME, Diegel M, Leshinsky N, Klaus SJ. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J Immunol 163: 6567-6574, 1999.
15. Cui P, Macdonald TL, Chen M, Nadler JL. Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes. Bioorg Med Chem Lett 16: 3401-3405, 2006.
16. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63: 1373-1405, 2003.
17. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folson AR, Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52: 1799-1805, 2003.
18. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317: 510-512, 2007.
19. Frangioudakis G, Garrard J, Raddatz K, Nadler JL, Mitchell TW, Schmitz-Peiffer C. Saturated- and n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors. Endocrinology 151: 4187-4196, 2010.
20. Gabriely I, Ma XU, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rosetti L, Barzilai N. Removal of visceral fat prevents insulin resistance and glucose tolerance of aging. Diabetes 51: 2951-2958, 2002.
21. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 5: 551-559, 2002.
22. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89: 2595-2600, 2004.
23. (a)Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS. 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes 57: 1387-1393, 2008.
24. Gustafson B, Gogg S, Hedjazifar S, Jenndahl L, Hammarstedt A, Smith U. Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am J Physiol Endocrinol Metab 297: E999-E1003, 2009.
25. Horrillo R, González-Périz A, Martínez-Clemente M, López-Parra M, Ferré N, Titos E, Morán-Salvador E, Deulofeu R, Arroyo V, Clària J. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 184: 3978-3987, 2010.
26. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue. Expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995.
27. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43: 1271-1278, 1994.
28. Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, Wright SD, Springer MS, Evans J, Cui J. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 24: 1748-1749, 2004.
29. Kaaman M, Rydén M, Axelsson T, Nordström E, Sicard A, Bouloumié A, Langin D, Arner P, Dahlman I. ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance. Int J Obes (Lond) 30: 447-452, 2006.
30. Kahn SE, Hull RL, Utzschneider KM. Mechanism linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846, 2006. (Pubitemid 46024990)
31. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 106: 473-481, 2000.
32. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494-1505, 2006.
33. Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, Natarajan R. 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int 59: 1354-1362, 2001.
34. Laybutt DR, Sharma A, Sgroi DC, Gaudet J, Bonner-Weir S, Weir GC. Genetic regulation of metabolic pathways in beta-cells disrupted by hyperglycemia. J Biol Chem 277: 10912-10921, 2002.
35. Lumeng CN, Maillard I, Saltiel AR. T-ing up inflammation in fat. Nat Med 15: 846-847, 2009.
36. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL. 12-Lipoxygenase Products Reduce Insulin Secretion and {beta}-Cell Viability in Human Islets. J Clin Endocrinol Metab 95: 887-893, 2010.
37. Manev H, Uz T. Primary culture of rat cerebellar granule cells as a model to study neuronal 5-lipoxygenase and FLAP gene expression. Ann NY Acad Sci 890: 183-190, 1999.
38. McDuffie M, Maybee NA, Keller SR, Stevens BK, Garmey GC, Morris MA, Kropf E, Rival C, Ma K, Carter JD, Tersey SA, Nunemaker CS, Nadler JL. Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes. Diabetes 57: 199-208, 2008.
39. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56: 45-62, 2005.
40. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 24: 1542-1548, 2004.
41. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136: 2143-2149, 1995.
42. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 116: 33-35, 2006.
43. Nunemaker CS, Chen M, Pei H, Kimble SD, Keller SR, Carter JD, Yang Z, Smith KM, Wu R, Bevard MH, Garmey JC, Nadler JL. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by western diet. Am J Physiol Endocrinol Metab 295: E1065-E1075, 2008.
44. Olefsky JM. IKKepsilon: a bridge between obesity and inflammation. Cell 138: 834-836, 2009.
45. Osher E, Weisinger G, Limor R, Tordjman K, Stern N. The 5 lipoxygenase system in the vasculature: emerging role in health and disease. Mol Cell Endocrinol 27: 201-206, 2006.
46. Pei H, Gu J, Thimmalapura PR, Mison A, Nadler JL. Activation of the 12-lipoxygenase and signal transducer and activator of transcription pathway during neointima formation in a model of the metabolic syndrome. Am J Physiol Endocrinol Metab 290: E92-E102, 2006.
47. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83: 346-356, 1977.
48. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241-1248, 1998.
49. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67: 291-300, 2000.
50. Qatanani M, Szwergold NR, Greaves DR, Rexford S, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 119: 531-539, 2009.
51. Rådmark O. 5-lipoxygenase-derived leukotrienes. Arterioscler Thromb Vasc Biol 23: 1140-1142, 2003.
52. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance and cardiovascular disease. Recent Prog Horm Res 59: 207-223, 2004.
53. Reilly KB, Srinivasan S, Hatley ME, Patricia MK, Lannigan J, Bolick DT, Vandenhoff G, Pei H, Natarajan R, Nadler JL, Hedrick CC. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem 279: 9440-9450, 2004.
54. Sears DD, Miles PD, Chapman J, Ofrecio JM, Almazan F, Thapar D, Miller YI. 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PloS One 4: e7250, 2009.
55. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92: 1023-1033, 2007.
56. Smith U, Hammarstedt A. Antagonistic effects of thiazolidinediones and cytokines in lipotoxicity. Biochim Biophys Acta 1801: 377-380, 2010.
57. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children. Circulation 107: 1448-1453, 2003.
58. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K, Minami I, Iwashima F, Sakai H, Tateno T, Sato R, Hirata Y. Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 336: 163-167, 2005.
59. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 10: 35-36, 2010.
60. Torpey N, Maher SE, Bothwell AL, Pober JS. Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells. J Biol Chem 279: 26789-26796, 2004.
61. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880, 2006.
62. Wegner M, Winiarska H, Bobkiewicz-Kozlowska T, Dworacka M. IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas. Cytokine 42: 312-316, 2008.
63. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
64. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350: 2362-2375, 2004.
65. Wen Y, Gu J, Li SL, Reddy MA, Natarajan R, Nadler JL. Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology 147: 2518-2525, 2006.
66. Wen Y, Gu J, Chakrabarti SK, Aylor K, Marshall J, Takahashi Y, Yoshimoto T, Nadler JL. The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in machrophages. Endocrinology 148: 1313-1322, 2007.
67. Wueest S, Rapold RA, Schumann DM, Rytka JM, Schildknecth A, Nov O, Chervonsky AV, Rudich A, Schoenle EJ, Donath MY, Konrad D. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestation of obesity in mice. J Clin Invest 120: 191-202, 2010.
68. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.
69. Yang Z, Chen M, Ellett JD, Fialkow LB, Carter JD, McDuffie M, Nadler JL. Autoimmune diabetes is blocked in Stat-4 deficient mice. J Autoimmun 22: 191-200, 2004.
70. Yang Z, Chen M, Nadler JL. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol 69: 1-5, 2005.